Study is to determine if a weekly dose of 17P (Progesterone) given to women with preterm rupture of the membranes will: increase the probability of continuing the pregnancy until a favorable gestational age.Increase the interval between randomization and delivery. Decrease neonatal morbidity.
The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery.
Study to determine if the drug 17-hydroxyprogesterone caproate can help reduce the risk of preterm delivery in women with certain risk factors for preterm birth. We hope to learn whether this same medication can be used to prolong pregnancy in a group of patients in whom this medication has not been previously studied. Specifically, we hope to learn whether progesterone supplementation will delay delivery in women with pre-term, premature rupture of membranes (PPROM).
Planned study is to determine if a weekly dose of Progesterone (17OHP) given to women with preterm rupture of the membranes will: 1.increase the probability of continuing the pregnancy until a favorable gestational age. 2.increase the interval between randomization and delivery.3.decrease neonatal morbidity.
Hypothesis of study is that among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm delivery.This study involves two concurrent double-blinded randomized clinical trials of 17OHP versus placebo. Each trial will test the efficacy and safety of 17OHP in women with a specific risk factor for preterm birth. The two risk factors to be studied are: Twin pregnancy - Triplet pregnancy